Rx. Radar

J9278Inj, carboplatin (avyxa)

Published CMS Medicare Part B payment-limit context for J9278, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.

CMS payment limit

$5.203
per 1 MG · Medicare Part B
Down 0.7%from $5.242 in 2026-Q2
Current quarter
2026-Q3FinalEffective July 1, 2026
Billing unit
1 MG

Payment limit over time

$5.2475$5.1975

2024-Q4: Not published; 2025-Q1: Not published; 2025-Q2: Not published; 2025-Q3: Not published; 2025-Q4: Not published; 2026-Q1: Not published; 2026-Q2: $5.242; 2026-Q3: $5.203

Ingredient appears in FDA shortage dataFDA’s latest completed shortage data includes an affected record matching the Carboplatin ingredient family (FDA data as of August 20, 2026).
Email me when FDA shortage status changes

Kyxata

Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.

Other Carboplatin presentations

1 other CMS code

Source-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.

Swipe to see all columns

HCPCSCMS descriptionCurrent quarter 2026-Q3Prior quarter 2026-Q2ChangeNDCsView history
J9045Carboplatin injection$3.153 per 50 MG$2.937 per 50 MGUp 7.4%

Put another code on your radar.

Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.

Explore CMS codes